
Keywords: ADT; androgen deprivation therapy; AE; adverse event; CRPC; castration-resistant prostate cancer; LHRH; luteinizing hormone-releasing hormone; mCRPC; metastatic CRPC; MFS; metastase-free survival; nmCRPC; non-metastatic CRPC; PFS; progression-free surviva